Dr. Annabelle Manalo on Wednesday and Today met over 400 members of the Pharmacy Society of Wisconsin including each of its board members of the Pharmacy Society of Wisconsin. Read More »
Nationwide demand for local pharmacy model fuels expansion Read More »
Within a week of FDA approval, MAVENCLAD has formulary coverage with one of the leading pharmacy benefit managers in the U.S. Read More »
Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study Read More »
In Honor of April's IBS Awareness Month, Efforts Highlight Advances in Research Read More »
New safes for controlled substances will help combat opioid epidemic in the state and reduce robbery incidents Read More »
Review follows rapid growth in product portfolio Read More »
Safe Rx announced its availability in selected California locations of The Medicine Shoppes, a leading franchised pharmacy store banner. Read More »
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea Read More »
Xynomic Pharmaceuticals, Inc. ("Xynomic"), a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corporation (Nasdaq: BCAC), jointly announced that Xynomic and its collaborators will present at the American Society of Clinical Oncology ("ASCO") 2019 Annual Meeting to be held in Chicago from May 31, 2019 - June 4, 2019. Read More »
New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy Read More »
Partnership to raise awareness of the increased burden of heart failure in African Americans and shed light on approaches to managing the unique challenges facing this patient community Read More »
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC), and olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases, at the 14th Congress of European Crohn's and Colitis Organisation (ECCO). Read More »
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced sale of certain assets to Bausch Health Companies Inc. is now complete. Read More »
Daiichi Sankyo Europe (hereafter, Daiichi Sankyo) and Esperion Therapeutics Inc. (hereafter, Esperion) announced today the validation of the Marketing Authorisation Application (MAA) for bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet by the European Medicines Agency (EMA) Read More »
Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes Read More »
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, a generic version of Indivior's Suboxone® Sublingual Film. Read More »
Diagnostic Solutions Laboratory (DSL) continues its innovative vision to transform and improve personalized medicine by introducing its first DNA SNP test, GenomicInsight™ Genomic Health Profile powered by Opus23 Explorer™, a proprietary version of DataPunk's Opus23 informatics software, conceived, developed, and coded by Dr. Peter D'Adamo, Distinguished Professor of Clinical Sciences, University of Bridgeport. Read More »
This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients Read More »
Alerts Sign-up
